Waldencast Reports Q2 2024 Financial Results

$63.3 million net sales Q2 2024
+25.7% net sales Comparable growth: +30.9% Obagi Medical and +20.0% Milk Makeup vs. Q2 2023
Adjusted EBITDA of $6.3 million, up +64.5% versus Q2 2023

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended June 30, 2024 (“Q2 2024”) and the six months ended June 30, 2024 (“H1 2024”) on Form 6-K filed with the U.S. Securities and Exchange Commission, which is also available on the Company’s Investor Relations website at http://ir.waldencast.com/.